C1QC: A Potential Drug Target Or Biomarker (G714)

Target Name: C1QC

NCBI ID: G714

C1QC

C1QC: A Potential Drug Target Or Biomarker

C1QC, also known as C1QC variant 2, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the cytoskeleton, which is the structure that gives cells their shape and helps them maintain their stability.

Recent studies have suggested that C1QC may be a drug target or biomarker for a variety of diseases. This is because the C1QC protein has been shown to play a role in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the reasons for the interest in C1QC is its role in the development of cancer. Many studies have shown that C1QC is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that C1QC may be a useful target for cancer therapies that target this protein.

In addition to its role in cancer development, C1QC has also been shown to be involved in the progression of neurodegenerative diseases. For example, studies have shown that C1QC is highly expressed in the brains of individuals with Alzheimer's disease, and that this protein may play a role in the development and progression of this disease.

Another potential application of C1QC is as a biomarker for autoimmune disorders. Many autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, involve the immune system attacking the body's own tissues. C1QC has been shown to be involved in the immune response, and may be a useful target for therapies aimed at reducing or treating autoimmune disorders.

While more research is needed to fully understand the role of C1QC in these diseases, it is clear that this protein has the potential to be a valuable drug target or biomarker. As such, researchers are currently working to develop strategies for using C1QC as a therapeutic agent.

Protein Name: Complement C1q C Chain

Functions: C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes

The "C1QC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1QC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets